Two Sigma Advisers’s Cocrystal Pharma COCP Stock Holding History

Two Sigma Advisers’s Portfolio COCP Stock Details COCP Fund Activity

Bought

Maintained

Sold

Quarter	Market Value	Status	Shares	Change in Stake	Trade Value	Portfolio Weight	Portfolio Position
2022 Q2	–	Sell	-1,083	Closed	-$7K	–	2689
2022 Q1	$7K	Sell	1,083 -3,392	-76%	-$22.6K	﹤0.01%	2705
2021 Q4	$35K	Sell	4,475 -317	-7%	-$3.25K	﹤0.01%	2511
2021 Q3	$60K	Buy	+4,792	New	+$63.4K	﹤0.01%	2357
2020 Q4	–	Sell	-5,042	Closed	-$56K	–	2418
2020 Q3	$56K	Buy	+5,042	New	+$92K	﹤0.01%	2318

Other funds holding COCP

Sabby Management Miami Beach, Florida $45.1M AUM 74.25% 1-Year Est. Return

Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return

Renaissance Technologies New York $63.9B AUM 45.56% 1-Year Est. Return

BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return

Geode Capital Management Boston, Massachusetts $1.61T AUM 30.72% 1-Year Est. Return

Morgan Stanley New York $1.66T AUM 25.57% 1-Year Est. Return

State Street Boston, Massachusetts $2.9T AUM 29.55% 1-Year Est. Return

Parallel Advisors San Francisco, California $5.56B AUM 17.89% 1-Year Est. Return

Verition Fund Management Greenwich, Connecticut $15.4B AUM 30.69% 1-Year Est. Return

Northern Trust Chicago, Illinois $757B AUM 28.64% 1-Year Est. Return

Two Sigma Advisers's COCP Position: Q2 2022 in Review

Two Sigma Advisers sold out of Cocrystal Pharma (COCP) in Q2 2022, closing a stake of 1,083 shares — an estimated $7K sold.

Two Sigma Advisers first reported a position in COCP in Q3 2020 and held it in 4 quarters. The position peaked at $60K in Q3 2021. 33 funds tracked by Wall St. Rank hold COCP as of Q2 2022.

Two Sigma Advisers reported no remaining Cocrystal Pharma position as of Q2 2022 after selling out during the quarter.
Two Sigma Advisers sold 1,083 Cocrystal Pharma shares in Q2 2022, an estimated $7K.
Two Sigma Advisers first reported a position in Cocrystal Pharma in Q3 2020 and held it in 4 quarters.
Two Sigma Advisers's Cocrystal Pharma position peaked at $60K in Q3 2021.
33 funds tracked by Wall St. Rank held Cocrystal Pharma as of Q2 2022.

Based on Two Sigma Advisers's 13F filing for Q2 2022, filed 15 Aug 2022.